Dermal bacterial LPS-stimulation reduces susceptibility to intradermal Trypanosoma brucei infection.
Animals
Disease Models, Animal
Disease Susceptibility
/ immunology
Female
Humans
Injections, Intradermal
Lipopolysaccharides
/ administration & dosage
Macrophage Colony-Stimulating Factor
/ administration & dosage
Macrophages
/ immunology
Mice
Mice, Transgenic
RAW 264.7 Cells
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
/ genetics
Recombinant Proteins
/ administration & dosage
Skin
/ immunology
Swine
Trypanosoma brucei brucei
/ immunology
Trypanosomiasis, African
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 05 2021
10 05 2021
Historique:
received:
06
11
2020
accepted:
19
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Infections with Trypanosoma brucei sp. are established after the injection of metacyclic trypomastigotes into the skin dermis by the tsetse fly vector. The parasites then gain access to the local lymphatic vessels to infect the local draining lymph nodes and disseminate systemically via the bloodstream. Macrophages are considered to play an important role in host protection during the early stage of systemic trypanosome infections. Macrophages are abundant in the skin dermis, but relatively little is known of their impact on susceptibility to intradermal (ID) trypanosome infections. We show that although dermal injection of colony stimulating factor 1 (CSF1) increased the local abundance of macrophages in the skin, this did not affect susceptibility to ID T. brucei infection. However, bacterial LPS-stimulation in the dermis prior to ID trypanosome infection significantly reduced disease susceptibility. In vitro assays showed that LPS-stimulated macrophage-like RAW264.7 cells had enhanced cytotoxicity towards T. brucei, implying that dermal LPS-treatment may similarly enhance the ability of dermal macrophages to eliminate ID injected T. brucei parasites in the skin. A thorough understanding of the factors that reduce susceptibility to ID injected T. brucei infections may lead to the development of novel strategies to help reduce the transmission of African trypanosomes.
Identifiants
pubmed: 33972588
doi: 10.1038/s41598-021-89053-2
pii: 10.1038/s41598-021-89053-2
pmc: PMC8110744
doi:
Substances chimiques
Csf1r protein, mouse
0
Lipopolysaccharides
0
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
0
Recombinant Proteins
0
Macrophage Colony-Stimulating Factor
81627-83-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9856Subventions
Organisme : Wellcome Trust
ID : 218492/Z/19/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/D/20231762
Pays : United Kingdom
Références
Front Immunol. 2018 Feb 15;9:218
pubmed: 29497418
Dev Biol. 2007 Aug 1;308(1):232-46
pubmed: 17597598
J Leukoc Biol. 2004 Aug;76(2):399-405
pubmed: 15136584
Curr Opin Immunol. 2020 Oct;66:65-73
pubmed: 32446136
Trans R Soc Trop Med Hyg. 1999 Mar-Apr;93(2):169-70
pubmed: 10450441
PLoS Negl Trop Dis. 2013;7(3):e2090
pubmed: 23516643
J Leukoc Biol. 2001 May;69(5):685-90
pubmed: 11358974
Front Immunol. 2019 Sep 11;10:2137
pubmed: 31572363
Infect Immun. 1994 May;62(5):2135-7
pubmed: 8168985
J Immunol. 1991 Jun 15;146(12):4338-43
pubmed: 1904079
J Immunol. 1999 Apr 1;162(7):3749-52
pubmed: 10201887
Vet Rec. 1982 Mar 27;110(13):295-302
pubmed: 7072104
J Exp Med. 1989 Mar 1;169(3):1011-20
pubmed: 2784476
Exp Parasitol. 1976 Dec;40(3):427-31
pubmed: 976425
Blood. 2003 Feb 1;101(3):1155-63
pubmed: 12393599
Blood. 2015 Feb 19;125(8):e1-13
pubmed: 25573988
An Acad Bras Cienc. 2006 Dec;78(4):645-65
pubmed: 17143404
Infect Immun. 1998 Sep;66(9):4068-72
pubmed: 9712749
Mol Ther. 2014 Sep;22(9):1580-92
pubmed: 24962162
J Biol Chem. 2017 Feb 17;292(7):2924-2932
pubmed: 28073916
Exp Parasitol. 1992 Nov;75(3):353-60
pubmed: 1426137
Infect Immun. 2001 Apr;69(4):2162-71
pubmed: 11254571
Acta Trop. 1977 Mar;34(1):35-41
pubmed: 67786
PLoS Pathog. 2016 Jul 21;12(7):e1005744
pubmed: 27441553
Pharmaceutics. 2020 Mar 25;12(4):
pubmed: 32218380
Int J Parasitol. 2001 May 1;31(5-6):575-87
pubmed: 11334945
Front Immunol. 2014 Nov 21;5:554
pubmed: 25484881
Parasitol Res. 1994;80(8):687-90
pubmed: 7886039
Curr Opin Immunol. 2007 Aug;19(4):448-53
pubmed: 17702561
Biochem Biophys Res Commun. 1990 Jul 16;170(1):96-103
pubmed: 2372300
PLoS Pathog. 2014 Sep 11;10(9):e1004372
pubmed: 25211233
Acta Trop. 1980 Dec;37(4):375-9
pubmed: 6110327
Front Immunol. 2020 Jun 12;11:1250
pubmed: 32595652
Sci Rep. 2018 Jul 25;8(1):11203
pubmed: 30046157
J Immunol. 2008 Sep 15;181(6):3733-9
pubmed: 18768823
PLoS One. 2014 Aug 19;9(8):e105429
pubmed: 25137049
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7778-E7787
pubmed: 27856732
N Engl J Med. 1993 Dec 30;329(27):2002-12
pubmed: 7504210
J Leukoc Biol. 2014 Aug;96(2):167-83
pubmed: 24721704
Microbes Infect. 2002 Jul;4(9):999-1006
pubmed: 12106794
J Immunol. 1977 Sep;119(3):950-54
pubmed: 894031
BMC Immunol. 2002 Jul 04;3:7
pubmed: 12098359
Parasite Immunol. 2019 Feb;41(2):e12609
pubmed: 30525202
PLoS Genet. 2017 Mar 6;13(3):e1006641
pubmed: 28263993